Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic

  • Sánchez, Domingo
  • Castilla-Martí, Miguel
  • Ruiz, Agustín
Building on previous studies that report thinning of the macula in Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients, the use of optical coherence tomography (OCT) has been proposed as a potential biomarker for AD. However, other studies contradict these results. A total of 930 participants (414 cognitively healthy people, 192 with probable amnestic MCI, and 324 probable AD patients) from a memory clinic were consecutively included in this study and underwent a spectral domain OCT scan (Maestro, Topcon) to assess total macular volume and thickness. Macular width measurements were also taken in several subregions (central, inner, and outer rings) and in layers such as the retinal nerve fiber (RNFL) and ganglion cell (CGL). The study employed a design of high ecological validity, with adjustment by age, education, sex, and OCT image quality. AD, MCI, and control groups did not significantly vary with regard to volume and retinal thickness in different layers. When these groups were compared, multivariate-adjusted analysis disclosed no significant differences in total (p = 0.564), CGL (p = 0.267), RNFL (p = 0.574), and macular thickness and volume (p = 0.380). The only macular regions showing significant differences were the superior (p = 0.040) and nasal (p = 0.040) sectors of the inner macular ring. However, adjustment for multiple comparisons nullified this significance. These results are not supporting existing claims for the usefulness of macular thickness as a biomarker of cognitive impairment in a memory unit. OCT biomarkers for AD should be subject to further longitudinal testing., The authors thank the study participants and their families for their collaboration, and Topcon for its reliability as technological partnership. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement N° 796706 awarded to MM; from Fundació ACE Institut Català de Neurociències Aplicades in Barcelona, Spain and from a donation of “La nit de l’Alzheimer”, a charity dinner initiative that took place on August 8th 2016 as part of the “Festival Castell de Peralada”. The neuro-ophthalmology exam devices were acquired with a grant EFSD/Lilly Mental Health and Diabetes 2013 Programme of the European Foundation for the Study of Diabetes (EFSD) awarded to the project “Retinal neurodegeneration in type 2 diabetes as biomarker of Alzheimer’s disease” under the leadership of CH. The present work was performed as part of Domingo Sánchez Ruiz’ doctoral program with title “Clinical Utility of OCT in diagnosing and monitoring of cognitive impairment” in the Department of Surgery and Morphological Sciences at Universitat Autonoma Barcelona (Barcelona, Spain).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

  • Marquié, Marta
  • Castilla-Martí, Miguel
  • Boada, Mercè
  • FACEHBI study group
Background: Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD. There is little data about retinal changes in preclinical AD and their correlation with amyloid-β (Aβ) uptake. Aims: We investigated the association of retinal thickness quantified by OCT with Aβ accumulation and conversion to mild cognitive impairment (MCI) over 24 months in individuals with SCD. Methods: One hundred twenty-nine individuals with SCD enrolled in Fundació ACE Healthy Brain Initiative underwent comprehensive neuropsychological testing, OCT scan of the retina and florbetaben (FBB) positron emission tomography (PET) at baseline (v0) and after 24 months (v2). We assessed the association of sixteen retinal thickness measurements at baseline with FBB-PET status (+/-) and global standardize uptake value ratio (SUVR) as a continuous measure at v0 and v2 and their predictive value on clinical status change (conversion to mild cognitive impairment (MCI)) at v2. Results: Mean age of the sample was 64.72 ± 7.27 years; 62.8% were females. Fifteen participants were classified as FBB-PET+ at baseline and 22 at v2. Every 1 μm of increased thickness in the inner nasal macular region conferred 8% and 6% higher probability of presenting a FBB-PET+ status at v0 (OR = 1.08, 95% CI = 1.02-1.14, p = 0.007) and v2 (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), respectively. Inner nasal macular thickness also positively correlated with global SUVR (at v0: β = 0.23, p = 0.004; at v2: β = 0.26, p = 0.001). No retinal measurements were associated to conversion to MCI over 24 months. Conclusions: Subtle retinal thickness changes in the macular region are already present in SCD and correlate with Aβ uptake., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706, and the Instituto de Salud Carlos III (ISCIII) grant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa") awarded to M.M. Funds were also obtained from donations from “La nit de l’Alzheimer”, a charity dinner initiative that takes place yearly as part of the “Festival Castell de Peralada” (2016-2018). The neuro-ophthalmology exam devices were acquired with a grant EFSD/Lilly Mental Health and Diabetes 2013 Programme of the European Foundation for the Study of Diabetes (EFSD) awarded to the project “Retinal neurodegeneration in type 2 diabetes as biomarker of Alzheimer’s disease” under the leadership of C.H. Funds from Fundació ACE Institut Català de Neurociències Aplicades, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa are supporting the FACEHBI study. These sponsors were not involved in the study design, data collection, analysis or interpretation. The sponsors have reviewed the manuscript and have given their approval.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study

  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Soldevila-Domenech, Natalia
  • Sánchez Benavides, Gonzalo
  • Shekari, Mahnaz
  • Vállez García, David
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • AMYPAD Consortium
Background: Poor self-reported sleep quality is associated with cognitive impairment. Alzheimer's disease (AD) patients present sleep disruptions decades before they start to decline clinically. Similarly, amyloid-ß (Aß) starts accumulating during the preclinical phase of the disease. This study investigated associations between self-reported sleep quality and Aß burden longitudinally in clinically unimpaired (CU) adults. Methods: Four hundred seventeen CU adults from the AMYPAD PNHS cohort were included, with baseline self-reported sleep quality assessments (Pittsburgh Sleep Quality Index, PSQI) and longitudinal Aß PET scans. Participants were categorized by baseline Aß levels as negative (A-), grey-zone (GZ), or positive (A+). Linear mixed-effects (LME) models tested the association between baseline sleep quality and Aß burden over time, including interaction effects with baseline Aß status. Results: Global PSQI score was not associated with Aß burden over time in the entire group. However, a significant interaction with baseline Aß status was found, whereby poorer subjective sleep quality was linked to accelerated Aß accumulation in GZ participants. Conclusions: Poorer subjective sleep quality is associated with faster Aß accumulation in CU individuals with intermediate Aß levels, highlighting sleep as a potential target for early AD prevention and identifying an optimal intervention window., OG-R received support from the grant IJC2020-043417-I, funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; this study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417" (OG-R). GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE +, and receives funding from the MCIN/AEI/https://doi.org/10.13039/501100011033 through the project PID2020-119556RA-I00 and through the project PID2024-163071OB-I00, funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union FEDER. This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The FACEHBI study was supported with funds from Ace Alzheimer Center Barcelona, Life Molecular Imaging, Grifols, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne, and IrsiCaixa. The FACEHBI study was part of the AMYPAD-PNHS project, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. MB received funding support from CIBERNED (Instituto de Salud Carlos III (ISCIII); EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975; EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100; MOPEAD, Innovative Medicine Initiative, Grant. Nº. 115,985; PreDADQoL, ERA-NET (call 2015). Grant nº AC15/00082; TARTAGLIA (Red federada para acelerar la aplicación de la inteligencia artificial en el sistema sanitario español); PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097; GECONEU Grant No. 2023–1-ELO1-KAZZ0-HED-000032173 co –founded by the European Union; Grants PI13/02434, PI16/01861, BA19/00020, and PI19/01301 from the Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”); Fundació “La Caixa” and Grífols (GR@ACE project); and Proyectos de Investigación de Medicina Personalizada (ISCIII), PMP-DEGESCO, Grant Nº PMP22/00022. MM has received funding support from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706, and the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—Una manera de hacer Europa) grant PI19/00335.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Visual impairment in aging and cognitive decline: experience in a memory Clinic

  • Marquié, Marta
  • Castilla-Martí, Miguel
  • Boada, Mercè
Visual impairment is common in people living with dementia and regular ophthalmological exams may improve their quality of life. We evaluated visual function in a cohort of elderly individuals and analyzed its association with their degree of cognitive impairment. Participants underwent neurological and neuropsychological exams, neuro-ophthalmological assessment (visual acuity, intraocular pressure, rates of past ophthalmological pathologies, use of ocular correction, treatments and surgeries) and optical coherence tomography (OCT) scan. We analyzed differences in ophthalmological characteristics among diagnostic groups. The final sample of 1746 study participants aged ≥ 50 comprised 229 individuals with Subjective Cognitive Decline (SCD), 695 with mild cognitive impairment (MCI) and 833 with Dementia (Alzheimer disease: n = 660; vascular dementia: n = 92, Lewy body dementia: n = 34; frontotemporal dementia: n = 19 and other: n = 28). Age, gender and education were used as covariates. Patients with Dementia, compared to those with SCD and MCI, presented worse visual acuity (p < 0.001), used less visual correction (p = 0.02 and p < 0.001, respectively) and fewer ophthalmological treatments (p = 0.004 and p < 0.001, respectively) and underwent fewer ocular surgeries (p = 0.009 and p < 0.001, respectively). OCT image quality worsened in parallel to cognitive decline (Dementia vs SCD: p = 0.008; Dementia vs MCI: p < 0.001). No group differences in past ophthalmological disorders or abnormal OCT findings were detected. Efforts should be made to ensure dementia patients undergo regular ophthalmological assessments to correct their visual function in order to improve their quality of life., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement N° 796706 awarded to MM; from Fundació ACE Institut Català de Neurociències Aplicades in Barcelona, Spain and from a donation of “La nit de l’Alzheimer”, a charity dinner initiative that took place on August 8th 2016 as part of the “Festival Castell de Peralada”. The neuro-ophthalmology exam devices were acquired with a grant EFSD/Lilly Mental Health and Diabetes 2013 Programme of the European Foundation for the Study of Diabetes (EFSD) awarded to the project “Retinal neurodegeneration in type 2 diabetes as biomarker of Alzheimer’s disease” under the leadership of CH.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

  • Marquié, Marta
  • Castilla-Martí, Miguel
  • Boada, Mercè
  • FACEHBI study group
Background: Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD. There is little data about retinal changes in preclinical AD and their correlation with amyloid-β (Aβ) uptake. Aims: We investigated the association of retinal thickness quantified by OCT with Aβ accumulation and conversion to mild cognitive impairment (MCI) over 24 months in individuals with SCD. Methods: One hundred twenty-nine individuals with SCD enrolled in Fundació ACE Healthy Brain Initiative underwent comprehensive neuropsychological testing, OCT scan of the retina and florbetaben (FBB) positron emission tomography (PET) at baseline (v0) and after 24 months (v2). We assessed the association of sixteen retinal thickness measurements at baseline with FBB-PET status (+/-) and global standardize uptake value ratio (SUVR) as a continuous measure at v0 and v2 and their predictive value on clinical status change (conversion to mild cognitive impairment (MCI)) at v2. Results: Mean age of the sample was 64.72 ± 7.27 years; 62.8% were females. Fifteen participants were classified as FBB-PET+ at baseline and 22 at v2. Every 1 μm of increased thickness in the inner nasal macular region conferred 8% and 6% higher probability of presenting a FBB-PET+ status at v0 (OR = 1.08, 95% CI = 1.02-1.14, p = 0.007) and v2 (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), respectively. Inner nasal macular thickness also positively correlated with global SUVR (at v0: β = 0.23, p = 0.004; at v2: β = 0.26, p = 0.001). No retinal measurements were associated to conversion to MCI over 24 months. Conclusions: Subtle retinal thickness changes in the macular region are already present in SCD and correlate with Aβ uptake., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706, and the Instituto de Salud Carlos III (ISCIII) grant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa") awarded to M.M. Funds were also obtained from donations from “La nit de l’Alzheimer”, a charity dinner initiative that takes place yearly as part of the “Festival Castell de Peralada” (2016-2018). The neuro-ophthalmology exam devices were acquired with a grant EFSD/Lilly Mental Health and Diabetes 2013 Programme of the European Foundation for the Study of Diabetes (EFSD) awarded to the project “Retinal neurodegeneration in type 2 diabetes as biomarker of Alzheimer’s disease” under the leadership of C.H. Funds from Fundació ACE Institut Català de Neurociències Aplicades, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa are supporting the FACEHBI study. These sponsors were not involved in the study design, data collection, analysis or interpretation. The sponsors have reviewed the manuscript and have given their approval.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic

  • Sánchez, Domingo
  • Castilla-Martí, Miguel
  • Ruiz, Agustín
Building on previous studies that report thinning of the macula in Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients, the use of optical coherence tomography (OCT) has been proposed as a potential biomarker for AD. However, other studies contradict these results. A total of 930 participants (414 cognitively healthy people, 192 with probable amnestic MCI, and 324 probable AD patients) from a memory clinic were consecutively included in this study and underwent a spectral domain OCT scan (Maestro, Topcon) to assess total macular volume and thickness. Macular width measurements were also taken in several subregions (central, inner, and outer rings) and in layers such as the retinal nerve fiber (RNFL) and ganglion cell (CGL). The study employed a design of high ecological validity, with adjustment by age, education, sex, and OCT image quality. AD, MCI, and control groups did not significantly vary with regard to volume and retinal thickness in different layers. When these groups were compared, multivariate-adjusted analysis disclosed no significant differences in total (p = 0.564), CGL (p = 0.267), RNFL (p = 0.574), and macular thickness and volume (p = 0.380). The only macular regions showing significant differences were the superior (p = 0.040) and nasal (p = 0.040) sectors of the inner macular ring. However, adjustment for multiple comparisons nullified this significance. These results are not supporting existing claims for the usefulness of macular thickness as a biomarker of cognitive impairment in a memory unit. OCT biomarkers for AD should be subject to further longitudinal testing., The authors thank the study participants and their families for their collaboration, and Topcon for its reliability as technological partnership. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement N° 796706 awarded to MM; from Fundació ACE Institut Català de Neurociències Aplicades in Barcelona, Spain and from a donation of “La nit de l’Alzheimer”, a charity dinner initiative that took place on August 8th 2016 as part of the “Festival Castell de Peralada”. The neuro-ophthalmology exam devices were acquired with a grant EFSD/Lilly Mental Health and Diabetes 2013 Programme of the European Foundation for the Study of Diabetes (EFSD) awarded to the project “Retinal neurodegeneration in type 2 diabetes as biomarker of Alzheimer’s disease” under the leadership of CH. The present work was performed as part of Domingo Sánchez Ruiz’ doctoral program with title “Clinical Utility of OCT in diagnosing and monitoring of cognitive impairment” in the Department of Surgery and Morphological Sciences at Universitat Autonoma Barcelona (Barcelona, Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study

  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Soldevila-Domenech, Natalia
  • Sánchez Benavides, Gonzalo
  • Shekari, Mahnaz
  • Vállez García, David
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • AMYPAD Consortium
Background: Poor self-reported sleep quality is associated with cognitive impairment. Alzheimer's disease (AD) patients present sleep disruptions decades before they start to decline clinically. Similarly, amyloid-ß (Aß) starts accumulating during the preclinical phase of the disease. This study investigated associations between self-reported sleep quality and Aß burden longitudinally in clinically unimpaired (CU) adults. Methods: Four hundred seventeen CU adults from the AMYPAD PNHS cohort were included, with baseline self-reported sleep quality assessments (Pittsburgh Sleep Quality Index, PSQI) and longitudinal Aß PET scans. Participants were categorized by baseline Aß levels as negative (A-), grey-zone (GZ), or positive (A+). Linear mixed-effects (LME) models tested the association between baseline sleep quality and Aß burden over time, including interaction effects with baseline Aß status. Results: Global PSQI score was not associated with Aß burden over time in the entire group. However, a significant interaction with baseline Aß status was found, whereby poorer subjective sleep quality was linked to accelerated Aß accumulation in GZ participants. Conclusions: Poorer subjective sleep quality is associated with faster Aß accumulation in CU individuals with intermediate Aß levels, highlighting sleep as a potential target for early AD prevention and identifying an optimal intervention window., OG-R received support from the grant IJC2020-043417-I, funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; this study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417" (OG-R). GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE +, and receives funding from the MCIN/AEI/https://doi.org/10.13039/501100011033 through the project PID2020-119556RA-I00 and through the project PID2024-163071OB-I00, funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union FEDER. This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The FACEHBI study was supported with funds from Ace Alzheimer Center Barcelona, Life Molecular Imaging, Grifols, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne, and IrsiCaixa. The FACEHBI study was part of the AMYPAD-PNHS project, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. MB received funding support from CIBERNED (Instituto de Salud Carlos III (ISCIII); EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975; EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100; MOPEAD, Innovative Medicine Initiative, Grant. Nº. 115,985; PreDADQoL, ERA-NET (call 2015). Grant nº AC15/00082; TARTAGLIA (Red federada para acelerar la aplicación de la inteligencia artificial en el sistema sanitario español); PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097; GECONEU Grant No. 2023–1-ELO1-KAZZ0-HED-000032173 co –founded by the European Union; Grants PI13/02434, PI16/01861, BA19/00020, and PI19/01301 from the Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”); Fundació “La Caixa” and Grífols (GR@ACE project); and Proyectos de Investigación de Medicina Personalizada (ISCIII), PMP-DEGESCO, Grant Nº PMP22/00022. MM has received funding support from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706, and the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—Una manera de hacer Europa) grant PI19/00335.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Visual impairment in aging and cognitive decline: experience in a memory Clinic

  • Marquié, Marta
  • Castilla-Martí, Miguel
  • Boada, Mercè
Visual impairment is common in people living with dementia and regular ophthalmological exams may improve their quality of life. We evaluated visual function in a cohort of elderly individuals and analyzed its association with their degree of cognitive impairment. Participants underwent neurological and neuropsychological exams, neuro-ophthalmological assessment (visual acuity, intraocular pressure, rates of past ophthalmological pathologies, use of ocular correction, treatments and surgeries) and optical coherence tomography (OCT) scan. We analyzed differences in ophthalmological characteristics among diagnostic groups. The final sample of 1746 study participants aged ≥ 50 comprised 229 individuals with Subjective Cognitive Decline (SCD), 695 with mild cognitive impairment (MCI) and 833 with Dementia (Alzheimer disease: n = 660; vascular dementia: n = 92, Lewy body dementia: n = 34; frontotemporal dementia: n = 19 and other: n = 28). Age, gender and education were used as covariates. Patients with Dementia, compared to those with SCD and MCI, presented worse visual acuity (p < 0.001), used less visual correction (p = 0.02 and p < 0.001, respectively) and fewer ophthalmological treatments (p = 0.004 and p < 0.001, respectively) and underwent fewer ocular surgeries (p = 0.009 and p < 0.001, respectively). OCT image quality worsened in parallel to cognitive decline (Dementia vs SCD: p = 0.008; Dementia vs MCI: p < 0.001). No group differences in past ophthalmological disorders or abnormal OCT findings were detected. Efforts should be made to ensure dementia patients undergo regular ophthalmological assessments to correct their visual function in order to improve their quality of life., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement N° 796706 awarded to MM; from Fundació ACE Institut Català de Neurociències Aplicades in Barcelona, Spain and from a donation of “La nit de l’Alzheimer”, a charity dinner initiative that took place on August 8th 2016 as part of the “Festival Castell de Peralada”. The neuro-ophthalmology exam devices were acquired with a grant EFSD/Lilly Mental Health and Diabetes 2013 Programme of the European Foundation for the Study of Diabetes (EFSD) awarded to the project “Retinal neurodegeneration in type 2 diabetes as biomarker of Alzheimer’s disease” under the leadership of CH.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Visual impairment in aging and cognitive decline, experience in a Memory Clinic

  • Marquié, Marta|||0000-0002-0660-0950
  • Castilla Marti, Miguel|||0000-0003-1886-3536
  • Valero, Sergi|||0000-0002-6599-948X
  • Martínez, Joan|||0000-0001-7962-709X
  • Sánchez, Domingo
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Vargas, Liliana|||0000-0001-5685-5903
  • Mauleón, Ana|||0000-0002-4218-2127
  • Rodríguez-Gómez, Octavio
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Espinosa, Ana|||0000-0001-7399-3267
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Moreno-Grau, Sonia
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Hernández, Cristina|||0000-0002-3109-1721
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Monté-Rubio, Gemma C.|||0000-0002-3532-2224
  • Benaque, Alba
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Luis
  • Boada, Mercè|||0000-0003-2617-3009
Visual impairment is common in people living with dementia and regular ophthalmological exams may improve their quality of life. We evaluated visual function in a cohort of elderly individuals and analyzed its association with their degree of cognitive impairment. Participants underwent neurological and neuropsychological exams, neuro-ophthalmological assessment (visual acuity, intraocular pressure, rates of past ophthalmological pathologies, use of ocular correction, treatments and surgeries) and optical coherence tomography (OCT) scan. We analyzed differences in ophthalmological characteristics among diagnostic groups. The final sample of 1746 study participants aged ≥ 50 comprised 229 individuals with Subjective Cognitive Decline (SCD), 695 with mild cognitive impairment (MCI) and 833 with Dementia (Alzheimer disease: n = 660; vascular dementia: n = 92, Lewy body dementia: n = 34; frontotemporal dementia: n = 19 and other: n = 28). Age, gender and education were used as covariates. Patients with Dementia, compared to those with SCD and MCI, presented worse visual acuity (p < 0.001), used less visual correction (p = 0.02 and p < 0.001, respectively) and fewer ophthalmological treatments (p = 0.004 and p < 0.001, respectively) and underwent fewer ocular surgeries (p = 0.009 and p < 0.001, respectively). OCT image quality worsened in parallel to cognitive decline (Dementia vs SCD: p = 0.008; Dementia vs MCI: p < 0.001). No group differences in past ophthalmological disorders or abnormal OCT findings were detected. Efforts should be made to ensure dementia patients undergo regular ophthalmological assessments to correct their visual function in order to improve their quality of life.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline, Fundació ACE Healthy Brain Initiative

  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Castilla Marti, Miguel|||0000-0003-1886-3536
  • Martínez, Joan|||0000-0001-7962-709X
  • Rodríguez-Gómez, Octavio
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Tartari, Juan Pablo
  • Monté-Rubio, Gemma C.|||0000-0002-3532-2224
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Moreno-Grau, Sonia
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Mauleón, Ana|||0000-0002-4218-2127
  • Vargas, Liliana|||0000-0001-5685-5903
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Espinosa, Ana|||0000-0001-7399-3267
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Lomeña, Francisco
  • Pavia, Javier
  • Vivas, Assumpta
  • Tejero, Miguel Ángel
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Hernández, Cristina|||0000-0002-3109-1721
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Benaque, Alba
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Boada, Mercè|||0000-0003-2617-3009
Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD. There is little data about retinal changes in preclinical AD and their correlation with amyloid-β (Aβ) uptake. We investigated the association of retinal thickness quantified by OCT with Aβ accumulation and conversion to mild cognitive impairment (MCI) over 24 months in individuals with SCD. One hundred twenty-nine individuals with SCD enrolled in Fundació ACE Healthy Brain Initiative underwent comprehensive neuropsychological testing, OCT scan of the retina and florbetaben (FBB) positron emission tomography (PET) at baseline (v0) and after 24 months (v2). We assessed the association of sixteen retinal thickness measurements at baseline with FBB-PET status (+/-) and global standardize uptake value ratio (SUVR) as a continuous measure at v0 and v2 and their predictive value on clinical status change (conversion to mild cognitive impairment (MCI)) at v2. Mean age of the sample was 64.72 ± 7.27 years; 62.8% were females. Fifteen participants were classified as FBB-PET+ at baseline and 22 at v2. Every 1 μm of increased thickness in the inner nasal macular region conferred 8% and 6% higher probability of presenting a FBB-PET+ status at v0 (OR = 1.08, 95% CI = 1.02-1.14, p = 0.007) and v2 (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), respectively. Inner nasal macular thickness also positively correlated with global SUVR (at v0: β = 0.23, p = 0.004; at v2: β = 0.26, p = 0.001). No retinal measurements were associated to conversion to MCI over 24 months. Subtle retinal thickness changes in the macular region are already present in SCD and correlate with Aβ uptake.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis

  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
  • Marquié, Marta|||0000-0002-0660-0950
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Hernández, Isabel|||0000-0001-8119-393X
  • Mauleón, Ana|||0000-0002-4218-2127
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Tartari, Juan P.
  • Vargas, Liliana|||0000-0001-5685-5903
  • Espinosa, Ana|||0000-0001-7399-3267
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Moreno-Grau, Sonia
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Boada, Mercè|||0000-0003-2617-3009
  • Valero, Sergi|||0000-0002-6599-948X
Neuropsychiatric symptoms (NPS) have been recently addressed as risk factors of conversion to Alzheimer's disease (AD) and other dementia types in patients diagnosed with Mild Cognitive Impairment (MCI). Our aim was to determine profiles based on the prominent NPS in MCI patients and to explore the predictive value of these profiles on conversion to specific types of dementia. A total of 2137 MCI patients monitored in a memory clinic were included in the study. Four NPS profiles emerged (classes), which were defined by preeminent symptoms: Irritability, Apathy, Anxiety/Depression and Asymptomatic. Irritability and Apathy were predictors of conversion to dementia (HR = 1.43 and 1.56, respectively). Anxiety/depression class showed no risk effect of conversion when compared to Asymptomatic class. Irritability class appeared as the most discriminant neuropsychiatric condition to identify non-AD converters (i.e., frontotemporal dementia, vascular dementia, Parkinson's disease and dementia with Lewy Bodies). The findings revealed that consistent subgroups of MCI patients could be identified among comorbid basal NPS. The preeminent NPS showed to behave differentially on conversion to dementia, beyond AD. Therefore, NPS should be used as early diagnosis facilitators, and should also guide clinicians to detect patients with different illness trajectories in the progression of MCI.